Search
Tetryzoline
go.drugbank.com/drugs/DB06764ApprovedTetryzoline, also known as tetrahydrozoline, is a derivative of imidazoline with central and peripheral alpha (α)-adrenergic properties. Available since the 1950s, tetryzoline is a selective α1-receptor agonist that is used as an ocular ...
Mixtures: Up and Up Ultra Itchy ReliefCopper
go.drugbank.com/drugs/DB09130ApprovedInvestigationalCopper is a transition metal and a trace element in the body. It is important to the function of many enzymes including cytochrome c oxidase, monoamine oxidase and superoxide dismutase [FDA Label]. Copper is commonly used in contraceptiv...
Cimlanod
go.drugbank.com/drugs/DB14983InvestigationalCimlanod is under investigation in clinical trial NCT02819271 (A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers)
NP-50301
go.drugbank.com/drugs/DB05662ExperimentalIt is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S.
Amphetamine
go.drugbank.com/drugs/DB00182ApprovedIllicitInvestigationalThis use derived into a large overproduction of amphetamine and all the surplus after the war finalized ended up in the black market, producing the initiation of the illicit abuse.[A18540]
Pentoxifylline
go.drugbank.com/drugs/DB00806ApprovedInvestigational[A226608] Pentoxifylline has been marketed in Europe since 1972; PTX extended-release tablets sold under the trade name TRENTAL by US Pharm Holdings were first approved by the FDA on Aug 30, 1984, but
Amisulpride
go.drugbank.com/drugs/DB06288ApprovedInvestigationalIn the US, the intravenous formulation of amisulpride is used to treat and prevent postoperative nausea and vomiting in adults, either as monotherapy or in combination with another antiemetic agent of
Sulisobenzone
go.drugbank.com/drugs/DB11185ApprovedSulisobenzone is approved by the FDA in concentrations of up to 10% and in Canada, is approved by Health Canada at the same concentrations [F38].
Efbemalenograstim alfa
go.drugbank.com/drugs/DB18704ApprovedInvestigationalThis approval was contingent on positive results observed in two pivotal Phase 3 Studies GC-627-04 and GC-627-05 in the US and Europe respectively.[L48887]
mRNA-1283
go.drugbank.com/drugs/DB22668ApprovedInvestigational[L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from